Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-01

Study Completion Date

2018-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia

NCT02731378

Chemotherapy-induced Anaemia

UNKNOWN PHASE4

Treatment Response in Dialysis Anaemia

NCT02707757

Anaemia Haemodialysis

COMPLETED PHASE4

Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis

NCT02403362

Chronic Renal Failure Chronic Kidney Disease Anemia

UNKNOWN PHASE2

A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

NCT04231292

Patient of Anemia in Chronic Renal Failure With Hemodialysis

UNKNOWN PHASE2

Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients

NCT01049711

Chronic Renal Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Erythropoiesis-stimulating agent (ESA) has been commonly used to manage patients with end-stage renal disease receiving dialysis. The effects of ESA, however, are unclear. This study compares the result of erythropoiesis-stimulating agent (ESA) versus supportive care for chronic kidney disease patients receiving palliative care. The investigators design a retrospective observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis. The primary objective is to assess whether ESA can reduce the transfusion burden and hospitalization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia of Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent

Erythropoiesis-Stimulating Agent

Intervention Type DRUG

erythropoiesis-stimulating agent: Mircera or Darbepoietin

Control Group

Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erythropoiesis-Stimulating Agent

erythropoiesis-stimulating agent: Mircera or Darbepoietin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 18 years and older, who opted for ESA treatment during palliative renal care for \> 360 days between January 1, 2014 and December 31, 2016